Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10911165 | Lung Cancer | 2014 | 4 Pages |
Abstract
Patients with thoracic tumors were determined to have an abnormally increased carboxyhemoglobin concentration of 2.1 ± 0.6%, indicative of hemeoxygenase-1 upregulation. It was found that 84% of thoracic tumor patients had plasma clot strength that exceeded the 95% confidence interval value observed in normal subjects, and 44% of this hypercoagulable subgroup had carboxyhemefibrinogen formation. Future investigation of the role played by plasmatic hypercoagulability and hemeoxygenase-1 derived carboxyhemefibrinogen in the pathogenesis of thoracic tumor related thrombophilia is warranted.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Vance G. Nielsen, Farid Gharagozloo, Ryan W. Matika, Samuel Kim, Eric A. Zelman, Evangelina B. Steinbrenner,